Thermodynamic rules for the design of high affinity HIV-1 protease inhibitors with adaptability to mutations and high selectivity towards unwanted targets

International Journal of Biochemistry and Cell Biology

Volumn 36, Issue 9, 2004, Pages 1787-1799

  Ohtaka, Hiroyasu ^a   Muzammil, Salman ^a   Schön, Arne ^a   Velazquez Campoy, Adrian ^a   Vega, Sonia ^a   Freire, Ernesto ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Adaptive inhibitors; AIDS; Binding thermodynamics; Drug resistance; Enzyme inhibition; HIV 1 protease; Isothermal titration calorimetry

Indexed keywords

PROTEINASE INHIBITOR; VIRUS PROTEIN;

BINDING AFFINITY; BIOMEDICAL ENGINEERING; DATA BASE; DRUG POTENCY; DRUG RESISTANCE; ENTHALPY; ENTROPY; EVOLUTIONARY ADAPTATION; GENE MUTATION; GENE TARGETING; GENETIC SUSCEPTIBILITY; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; REVIEW; THERMODYNAMICS; VIRUS GENE;

DRUG DESIGN; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTATION; SENSITIVITY AND SPECIFICITY; THERMODYNAMICS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 2942557079     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2004.02.021     Document Type: Review

References (40)

1. Ala P.J., Huston E.E., Klabe R.M., McCabe D.D., Duke J.L., Rizzo C.J., Korant B.D., DeLoskey R.D., Lam P.Y.S., Hodge C.N., Chang C.H. Molecular basis of HIV-1 protease drug resistance: Structural analysis of mutant proteases complexed with cyclic urea inhibitors. Biochemistry. 36:1997;1573-1580
2. Boden D., Markowitz M. Resistance to immunodeficiency virus type 1 protease inhibitors. Antimicrobial Agents and Chemotherapy. 42:1998;2775-2783
3. Condra J.H., Schleif W.A., Blahy O.M., Gabryelski L.J., Graham D.J., Quintero J.C., Rhodes A., Robbins H.L., Roth E., Shivaprakash M., Titus D., Yang T., Teppler H., Squires K.E., Deutsch P.J., Emini E.A. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 374:1995;569-571
4. Freire E. Designing drugs against heterogeneous targets. Nature Biotechnology. 20:2002;15-16
5. Gulnik, S., Erickson, J. W., & Xie, D. (1999). HIV protease: Enzyme function and drug resistance. In G. Litwack (Ed.), Vitamins and hormones. New York: Academic Press.
6. Gulnik S., Suvorov L.I., Liu B., Yu B., Anderson B., Mitsuya H., Erickson J.W. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry. 34:1995;9282-9287
7. Hertogs K., Bloor S., Kemp S.D., Van den Eynde C., Alcorn T.M., Pauwels R., Van Houtte M., Staszewski S., Miller V., Larder B.A. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: A survey of over 6000 samples. AIDS. 14(9):2000;1203-1210
8. Ho D.D., Toyoshima T., Mo H., Kempf D.J., Norbeck D., Chen C., Wideburg N.E., Burt S.K., Erickson J.W., Singh M.K. Characterization of human immunodeficiency virus type 1 variants with increased resistant to a C2-symmetric protease inhibitor. Journal of Virology. 68:1994;2016-2020
9. Hong L., Treharne A., Hartsuck J.A., Foundling S., Tang J. Crystal structures of complexes of a peptidic inhibitor with wild-type and two mutant HIV-1 proteases. Biochemistry. 35:1996;10627-10633
10. Jadhav P.K., Ala P., Woerner F.J., Chang C.H., Garber S.S. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency agains both wild type and protease inhibitor resistant mutants of HIV. Journal of Medicinal Chemistry. 40:1997;181-191
11. Kaplan A.H., Michael S.F., Wehbie R.S., Knigge M.F., Paul D.A., Everitt L., Kempf D.J., Norbeck D.W., Erickson J.W. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proceedings of the National Academy of Sciences of the United States of America. 91:1994;5597-5601
12. Kempf D.J., Marsh K.C., Denissen J.F., McDonald E., Vasavanonda S., Flentge C.A., Green B.E., Fino L., Park C.H., Kong X.P., et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proceedings of the National Academy of Sciences of the United States of America. 92(7):1995;2484-2488
13. Kiso Y. Design and synthesis of substrate-based peptidomimetic human immunodeficiency virus protease inhibitors containing the hydroxymethylcarbonyl isostere. Biopolymers. 40(2):1996;235-244
14. Kitchin J., Bethell R.C., Cammack N., Dolan S., Evans D.N., Holman S., Holmes D.S., McMeekin P., Mo C.L., Nieland N., et al. Synthesis and structure-activity relationships of a series of penicillin-derived HIV proteinase inhibitors: Heterocyclic ring systems containing P1′ and P2′ substituents. Journal of Medicinal Chemistry. 37(22):1994;3707-3716
15. Kozal M.J., Shah N., Shen N., Yang R., Fucini R., Merigan T.C., Richman D.D., Morris D., Hubbell E., Chee M., Gingeras T.R. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nature Medicine. 2(7):1996;753-759
16. Muzammil S., Ross P., Freire E. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance. Biochemistry. 42:2003;631-638
17. Navia M.A., Sato V.L., Tung R.D. Design of VX-478, a potent inhibitor of HIV protease. International Antiviral News. 3(9):1995;143-145
18. Nezami A., Freire E. The integration of genomic and structural information in the development of high affinity plasmepsin inhibitors. International Journal of Parasitology. 32:2002;1669-1676
19. Nezami A., Kimura T., Hidaka K., Kiso A., Liu J., Kiso Y., Goldberg D.A., Freire E. High affinity inhibition of a family of Plasmodium falciparum proteases by a designed adaptive inhibitor. Biochemistry. 42:2003;8459-8464
20. Ohtaka H., Schon A., Freire E. Multi drug-resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations. Biochemistry. 42:2003;13659-13666
21. Ohtaka H., Velazquez-Campoy A., Xie D., Freire E. Overcoming drug resistance in HIV-1 chemotherapy: The binding thermodynamics of Amprenavir and TMC-126 to wild type and drug-resistant mutants of the HIV-1 protease. Protein Science. 11:2002;1908-1916
22. Patick A.K., Mo H., Markowitz M., Appelt K., Wu B., Musick L., Kalish V., Kaldor S., Reich S., Ho D., Webber S. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrobial Agents and Chemotherapy. 40(2):1996;292-297
23. Reiling K.K., Endres N.F., Dauber D.S., Craik C.S., Stroud R.M. Anisotropic dynamics of the JE-2147-HIV protease complex: Drug resistance and thermodynamic binding mode examined at 1.09 Å structure. Biochemistry. 41:2002;4582-4594
24. Roberts N.A. Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors. AIDS. 9:1995;S27-S32
25. Schon A., Ingaramo M., Freire E. The binding of HIV-1 protease inhibitors to human serum proteins. Biophysical Chemistry. 105:2003;221-230
26. Shafer R.W., Chuang T.K., Hsu P., White C.B., Katzenstein D.A. Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type I seroconverters in Zimbawe. AIDS Research and Human Retroviruses. 15:1999;65-69
27. Todd M.J., Luque I., Velazquez-Campoy A., Freire E. The thermodynamic basis of resistance to HIV-1 protease inhibition. Calorimetric analysis of the V82F/I84V active site resistant mutant. Biochemistry. 39:2000;11876-11883
28. Vega, S., Kan, L. W., Velazquez-Campoy, A., Kiso, Y., Amzel, L. M., Freire, E. (2003). A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
29. Velazquez-Campoy A., Freire E. Incorporating target heterogeneity in drug design. Journal of Cellular Biochemistry. S37:2001;82-88
30. Velazquez-Campoy A., Kiso Y., Freire E. The binding energetics of first and second generation HIV-1 protease inhibitors: Implications for drug design. Archives of Biochimica and Biophysica. 390:2001;169-175
31. Velazquez-Campoy A., Luque I., Freire E. The use of isothermal titration calorimetry in drug design: Applications to high affinity binding and protonation/deprotonation coupling. Netsu Sokutei. 28:2001a;68-73
32. Velazquez-Campoy A., Luque I., Freire E. The application of thermodynamic methods in drug design. Thermochimica Acta. 380:2001b;217-227
33. Velazquez-Campoy A., Luque I., Todd M.J., Milutinovich M., Kiso Y., Freire E. Thermodynamic dissection of the binding energetics of KNI-272, a powerful HIV-1 protease inhibitor. Protein Science. 9:2000;1801-1809
34. Velazquez-Campoy A., Muzammil S., Ohtaka H., Schon A., Vega S., Freire E. Structural and thermodynamic basis of resistance to HIV-1 protease inhibition: Implications for inhibitor design. Current Drug Targets - Infectious Disorders. 3:2003a;311-328
35. Velazquez-Campoy A., Todd M.J., Freire E. HIV-1 protease inhibitors: Enthalpic versus entropic optimization of the binding affinity. Biochemistry. 39:2000;2201-2207
36. Velazquez-Campoy A., Todd M.J., Vega S., Freire E. Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes. Proceedings of the National Academy of Sciences of the United States of America. 98:2001;6062-6067
37. Velazquez-Campoy A., Vega S., Fleming E., Bacha U., Sayed Y., Dirr H.W., Freire E. Protease inhibition in African subtypes of HIV-1. AIDS Reviews. 5:2003b;165-171
38. Velazquez-Campoy A., Vega S., Freire E. Amplification of the effects of drug-resistance mutations by background polymorphisms in HIV-1 protease from African subtypes. Biochemistry. 41:2002;8613-8619
39. Wu T.D., Schiffer C.A., Gonzales M.J., Taylor J., Kantor R., Chou S., Israelski D., Zolopa A.R., Fessel W.J., Shafer R.W. Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. Journal of Virology. 77(8):2003;4836-4847
40. Yoshimura K., Kato R., Kavlick M.F., Nguyen A., Maroun V., Maeda K., Hussain K.A., Ghosh A.K., Gulnik S.V., Erickson J.W., Mitsuya H. A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and the selection of a novel (A28S) mutation in the protease active site. Journal of Virology. 76:2002;1349-1358